TrialDiabetes care2011

A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.

Tim Heise et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.